By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
IndebtaIndebta
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Notification Show More
Aa
IndebtaIndebta
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
Indebta > Markets > Madrigal Pharmaceuticals and Bioventus Stock See Action From Activist Investors
Markets

Madrigal Pharmaceuticals and Bioventus Stock See Action From Activist Investors

News Room
Last updated: 2023/06/23 at 9:43 PM
By News Room
Share
4 Min Read
SHARE

These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from June 15 through June 21, 2023. Source: VerityData

Contents
Activist Holdings Increases in HoldingsDecreases in Holdings

Activist Holdings

Madrigal Pharmaceuticals
(MDGL)

Baker Bros. Advisors owns 1,545,113 common shares of the pharmaceutical firm. That figure excludes 1.97 million and 400,000 series A and B convertible preferred securities, respectively, that currently cannot be converted due to ownership limitations.

Baker Bros. filed as an activist investor on June 15, as its co-founder Julian Baker and managing director Raymond Cheong were appointed to Madrigal’s board that day, with Julian Baker elected chairman. Baker Bros. remains one of Madrigal’s larger shareholders with an 8.4% stake.

Increases in Holdings

Bioventus
(BVS)

Juniper Investment raised its position in the maker of medical devices to 6,656,987 shares, excluding those held by Juniper Investment co-founder John Bartholdson. Juniper Investments purchased 747,851 Bioventus shares from June 12 through June 15 at per-share prices ranging from $2.72 to $3.63.

Following the fresh investment, Juniper Investment holds 10.7% of Bioventus’ tradable stock. Bartholdson was appointed to Bioventus’ board this January. Bioventus has gained 15% year to date, though it trades well below an all-time high of $19.94 reached in late June 2021.

Decreases in Holdings

GMS
(GMS)

Coliseum Capital trimmed its interest in the building-materials company to 4,772,485 shares. From June 12 through 16, Coliseum Capital sold 1,564,088 GMS shares at prices ranging from $66.01 to $68.80 each. Following those sales, Coliseum holds 11.6% of GMS’ outstanding stock.

GMS reported a strong fourth quarter on June 22. RBC Capital Markets analyst Mike Dahl lifted his price target on GMS stock to $68 from $55, and kept a Sector Perform rating. Dahl wrote in a research report, “[W]e still see a balanced risk/reward following the recent rally in the stock.”

Expro Group Holdings
(XPRO)

Oak Hill Advisors reduced its holding in the well services firm to 17,774,045 shares, excluding shares underlying restricted stock. Oak Hill Advisors executed a block trade sale of 2,320,000 Expro Group shares at a price of $17.37 apiece on June 13. No reason was cited for the sale that leaves Oak Hill with nearly 16.4% of Expro Group’s tradable stock.

Mercury Systems
(MRCY)Starboard Value cut its stake by nearly a third in the government and aerospace contractor to 2,660,258 shares. Starboard Value sold 1,112,033 Mercury Systems shares at prices ranging from $40.78 and $43.19 apiece from June 6 through June 14.

Starboard now owns 4.6% of Mercury Systems, below the 5% threshold that would require the disclosure of any further Mercury Systems stock sales.

Email: [email protected]

Read the full article here

News Room June 23, 2023 June 23, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
Netflix stock falls after Q3 earnings miss, Tesla preview, OpenAI announces new web browser

Watch full video on YouTube

Why Americans are obsessed with denim

Watch full video on YouTube

Why bomb Sokoto? Trump’s strikes baffle Nigerians

It was around 10pm on Christmas Day when residents of the mainly…

Pressure grows on Target as activist investor builds stake

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

Mosque bombing in Alawite district in Syria leaves at least 8 dead

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

- Advertisement -
Ad imageAd image

You Might Also Like

Crypto

'Fundamental Shift' in Traditional Bitcoin Market Cycle May Be on the Horizon

By News Room
Crypto

FTX/Alameda Unstakes Over $1B in Solana – Is a Major Price Shift Coming?

By News Room
Crypto

Mastercard Launches “Crypto Credential” To Replace Wallet Addresses With Usernames

By News Room
Crypto

Polygon Executive Pivots Roles To Developing ZK Proof Tech

By News Room
Crypto

Altcoin Interest Driving South Korean Crypto Craze – Report

By News Room
Crypto

Russian Central Bank Flags Sharp Rise in Crypto-related Activity

By News Room
Crypto

BitGo’s $100M Suit Against Galaxy Gets Green Light from Delaware Supreme Court

By News Room
Crypto

Here Are Your Top Crypto Gainers Today on DEXScreener

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?